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Mitochondria are subcellular, membrane-enclosed, organelles that 
are essential for cell survival in eukaryotes. These dynamic organelles 
are fundamental for energy production, providing substrates for 
intracellular metabolic pathways. Mitochondria also influence cellular 
signaling and survival pathways, including apoptosis [ ]. 
Mitochondrial dysfunction has been implicated in a plethora of 
human diseases, most notably in cancer and aging.  
Lung cancer is the most common type of cancer diagnosed in the 
world [2] and is the number one cancer killer in the United States [3]. 
It accounts for approximately 4% of all cancer diagnoses and 28% 
of cancer-attributed deaths in Americans [3]. Survival rates among 
patients with lung cancer are much lower than survival rates for 
patients with other common cancers, such as breast, colon or prostate 
cancer. The five-year survival rate for early stage lung cancer is 52.6% 
and for metastatic lung cancer is only 3.5%; approximately half of all 
patients die within a year of their initial diagnosis [4]. Screening 
options for lung cancer are very limited - only 5% of cases are 
diagnosed at an early stage [4]. Additionally, treatment is often 
ineffective, as evidenced by low survival rates, and costs an estimated 
0.3 billion dollars in the United States annually [5]. This review will 
highlight the roles of mitochondrial-mediated apoptosis in lung 
cancer and summarize the potential impact of mitochondrial 
dysfunction on tumorigenesis, including the contribution of 
mitochondrial dynamics to lung cancer progression. Currently, the 
mitochondria are viable targets for both diagnostic screening and 
therapeutics and further understanding of their contribution to cancer 










Mitochondrial dysfunction in lung cancer: Altered 
bioenergetics and genomic instability 
 
Mitochondria possess their own double-stranded circular genome, 
encoding 3 genes whose protein products are subunits of the 
respiratory chain or the oxidative phosphorylation system 
(OXPHOS). Mitochondrial DNA (mtDNA) is present in high copy 
numbers ( 03- 04 copies per cell) in virtually all cells. Electron 
transport and ATP synthesis by oxidative phosphorylation act 
continuously within a mitochondrion. The electron transport chain 
(ETC), organized into five separate enzymes (Complexes I-V), resides 
in the inner mitochondrial membrane and is the common pathway by 
which electrons, derived from energy rich molecules, flow to oxygen. 
Complexes I through IV each contain part of the electron transport 
chain, whereas Complex V catalyzes the synthesis of ATP. The final 
acceptor of the electrons is oxygen, which is reduced to water by the 
addition of four electrons.  
During mitochondrial respiration (most notably by Complexes I 
and III), toxic superoxide anion radicals are deleteriously produced 
when electrons are captured by oxygen. These superoxide radicals  
(O2-•) are converted to hydrogen peroxide (H2O2) by the 
mitochondrial enzymes manganese superoxide dismutase, SOD2 
(matrix localization) and cooper/zinc superoxide dismutase, SOD  
(intermembrane space localization). Within the mitochondria 
hydrogen peroxide is broken down to water by the action of 
glutathione peroxidases (GPX) or peroxiredoxins.  In addition to the 
antioxidant enzymes mentioned above, cells have nonenzymatic 
scavengers (glutathione, vitamins E and C, ubiquinone) to protect 
against reactive oxygen species (ROS). Complexes I, II and III 
subunits are all capable of generating ROS during OXPHOS and 
oxidative stress is the result of an imbalance between ROS production 
and antioxidant action. During conditions of high radical production 
or low antioxidation, these ROS can affect cell integrity, which can 
damage macromolecules such as lipids, proteins and DNA. The 
Complex I subunit has a special significance in tumor progression and 
metastasis. If Complex I is mutated, it will not interact with Complex 
III in supercomplexes, which results in the incorrect number of 
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electrons being transferred and, eventually, ROS overproduction 
cannot be detected by these cells. This results in an overproduction of 
ROS, increased energy loss, and oxidative stress [6]. In lung cancer, 
Complex I frequently appears to be altered, especially in patients that 
have never smoked. Forced over expression of mutated Complex I in 
mitochondria increased invasion, superoxide particles, and 
proliferation in vitro [7].  
Mitochondrial dysfunction, including metabolic alterations, has 
been observed in cancer cells. For instance, many tumor cells exhibit 
excessive glucose conversion to lactic acid in the presence of oxygen 
(aerobic glycolysis) as well as concomitantly suppressed mitochondrial 
respiration, a phenomenon known as the Warburg effect [8]. The 
Warburg effect in cancer cells demonstrates that mitochondria are 
dysfunctional by utilizing glycolysis to generate ATP. Despite oxygen 
being present, tumor cells prefer to generate ATP rapidly via 
glycolysis, which produces 6-fold less ATP than OXPHOS, but 
facilitates the increased rates of cell growth and proliferation [9]. 
When the balance between glycolysis and oxidative phosphorylation is 
disrupted, mitochondrial metabolites accumulate in the cytoplasm and 
influence metabolism. A side effect of such an imbalance is hypoxia or 
low oxygen levels. Unbridled cell proliferation within a tumor 
inevitably outgrows its blood supply, which lowers oxygen availability 
and cells enter a hypoxic state. These hypoxic conditions are thought 
to drive cancer progression by promoting genomic instability [ 0]. In 
the A549 lung cancer cell line, mitochondria are enlarged when in a 
hypoxic state; enlarged mitochondria appear to be resistant to 
apoptosis and thus allow cancer cells to continue proliferating [ ]. 
Hypoxic conditions stabilize the hypoxia-inducible transcription 
factor (HIF- α), which facilitates cells adapting to stressful 
environments by transcribing and synthesizing ~70 hypoxia-related 
factors [ 2]. HIF- α and other factors such as mutations in 
oncogenes, tumor suppressors and/or signaling kinases help to 
regulate glycolytic conversion and compensate for low-ATP yields in 
cancer [ 3- 6]. When cells are stressed for energy sources, AMPK (5’ 
adenosine monophosphate-activated protein kinase) is activated due 
to an increase in the AMP/ATP ratio. This inhibits cell proliferation 
and the cell begins making energy via oxidative metabolic pathways 
[ 7- 9]. In order to grow, tumor cells suppress AMPK signaling by 
altering signaling pathways and oncogenic mutations [ 9]. AMPK 
suppression allows tumor cells to grow under abnormally low nutrient 
conditions and cells proliferate [ 9], bypassing typical growth 
checkpoints via oncogene expression and loss of tumor suppressing 
genes (such as p53). The loss of AMPK signaling and the cascade of 
effects thereafter contribute to tumor growth and likely to energy 
production using glycolysis [20]. For example, the oncogene, c-myc, is 
overexpressed in 20% of cancers and contributes to tumor cell 
proliferation [2 ], enhances glycolysis and its production of 
precursors [ 2,22] and coordinates the regulation of metabolic 
networks to allow rapid entry into the cell cycle [23]. Additionally, 
the tumor suppressor p53, which is mutated or deleted in 50% of 
solid tumors [24], no longer induces cell-cycle arrest, apoptosis, DNA 
repair or senescence in response to cellular stress. Lack of p53 
function has been found to be advantageous for tumor cells by 
downregulating hypoxia-induced apoptosis [24-27] and interfering 
with ETC assembly and promoting a shift in metabolism to a more 
glycolytic state [28]. As such, killing lung cancer cells using a 
glycolytic inhibitor is more efficient in cells without functional p53 
[29]. The loss of tumor suppressors (p53) or the activation of 
oncoproteins effect the onocogenic signaling pathways, thus 
impacting cancer cell growth and survival [30]. Additional changes in 
metabolism are influenced by activation of Akt (acute transforming 
retrovirus thymoma protein kinase), which is often observed in cancer 
cells [ 2]; in fact, many studies point to the contribution of 
deregulated Akt in the development or progression of lung cancer 
[3 ]. For example, increased glycolytic capacity caused by complex 
transcriptional changes, such as inhibition of the forkhead box 
subfamily O (FOXO) transcription factors, is associated with changes 
in Akt  signaling and cellular transformation processes [30]. 
However, current debates in the field address whether changes in 
metabolism are a cause or consequence of neoplastic transformation 
[ 2]. 
Mitochondria are continuously exposed to mutagenic oxygen 
radicals generated by OXPHOS [32]; consequently, oxidative stress 
can alter the structure of the respiratory chain and cause proton 
leakage, mitochondrial uncoupling and mitochondrial DNA damage 
[33]. As such, mitochondrial DNA (mtDNA) acquire 0-fold more 
mutations than nuclear genomic DNA primarily because the 
mitochondrial genome lacks protective histones, introns and efficient 
DNA repair systems. Additionally, antioxidant defense mechanisms 
that protect the cell from damaging reactive oxygen species (ROS) are 
deficient in tumor cells [34,35]. Persistent oxidative stress in cells 
promotes DNA damage and subsequent cancer growth and metastasis. 
As such, mutations in mtDNA have been reported in human cancers 
[36-4 ]. Alterations of the non-coding displacement (D) loop of 
mtDNA are present in many cancers [42]. Fliss et al analyzed 
mutations in mtDNA in bladder, head and neck, and lung cancer and 
found mutations in 50% of cancers of which 67% were in the 
mtDNA D-loop region, suggesting a veritable genomic instability 
hot-spot [38]. Significantly elevated mutation rates in the mtDNA D-
loop region were observed in exhaled breath condensate of patients 
with lung cancer when compared to non-diseased controls; it has been 
proposed that mtDNA mutations may be a marker of carcinogenesis 
of the lung [43].  
In addition to mtDNA mutation, mtDNA content is positively 
associated with the risk of lung cancer [44,45]. It has been suggested 
that mtDNA content is thought to increase during tumorigenesis to 
compensate for mitochondrial dysfunction or damage [45]. However, 
it is unclear whether these alterations contribute to tumorigenesis or 
are a secondary consequence of the carcinogenic process. To better 
address this issue, studies utilizing techniques in next-generation 
sequencing for the rapid-high-throughput detection of mtDNA 
mutations or mtDNA content have allowed for examination of 
various tissues and body fluids in cancer patients to help address the 
timing of mtDNA alterations in the course of disease development 
[46]. As, such mitochondrial mutations and content are being 
explored as molecular markers of cancer detection and progression.  
Mitochondrial DNA is also susceptible to damage by 
environmental carcinogens, such as smoking [46]. Inequality between 
the frequency and nature of mtDNA mutations between smoker- and 
non-smoker lung cancer patients has recently been revealed to expand 
upon the impact of smoking on lung tumorigenesis. With no 
associations observed between mtDNA mutations with neither age 
nor gender, the frequency of mtDNA mutation was significantly 
higher in non-smokers when compared to smokers [7]. This smoking-
independent pathway for acquiring mtDNA mutation gives insight 
into understanding the mitochondrial genetic alterations of these 
more common new lung cancer cases being seen in clinical settings. 
However, the majority of the coding mtDNA mutations identified 
targeted complex I of the respiratory chain and ectopic expression of 
these mutations increased cellular proliferation, invasion and ROS 
production in lung cancer cells in vitro [7]. To support this 
observation, Complex I (NADH dehydrogenase) activity has been 
shown to be decreased in cells  with  high  metastatic  potential [47].  
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Furthermore, complex I deficiencies alter mitochondrial 
morphological phenotypes [48], which are indicative of mitochondrial 
health (as will be discussed later in the review), and influence the 
initiation of apoptosis - another key function of mitochondria, which 
is to control programmed cell death. Additionally, mitochondrial 
permeability transition (MPT) is the sudden permeabilization of the 
inner mitochondrial membrane in response to stimuli such as 
increased ROS production or hypoxia that can lead to mitochondrial 
swelling and apoptotic cell death. The mitochondrial permeability 
transition pore complex (PTPC) is a multimeric protein complex that 
spans both mitochondrial membranes and contains the following 
proteins: voltage-dependent anion channel (VDAC), adenine 
nucleotide translocase (ANT), cyclophilin D (CYPD), and peripheral 
benzodiazepine receptor (PBR) [49]. Alterations of the PTPC and its 
influence on apoptotic circumvention in lung cancer will be discussed 
in the next section.  
Figure  illustrates the bioenergetic alterations and genomic 
instability that occurs in lung cancer as a consequence of 
mitochondrial dysfunction.  
Mitochondrial-mediated apoptosis and lung oncogenesis 
 
Apoptosis is an evolutionarily conserved multistage process that 
maintains homeostasis in adult tissues [50]. Cancer cells have a variety 
of ways of preventing apoptosis, such as the mutation of apoptotic-
promoting proteins, anti-apoptotic proteins, and mitochondrial 
dysfunction [6]. Mitochondrial DNA mutations also appear to allow 
cancer cells to evade apoptosis [5 ]. A classic cancer hallmark 
proposed by Hanahan and Weinberg is apoptotic resistance. It is 
important to understand the molecular events that contribute to drug-
induced apoptosis and how tumors evade apoptotic cell death as many 
cancer treatments attempt to induce apoptosis in cancer cells but 
activation of the apoptotic machinery is not always effective.  
Defects in apoptosis are implicated in both tumorigenesis and 
drug resistance, and these defects are one cause of chemotherapy 
failures. The type of cancer determines its sensitivity to apoptosis. For 
example in lung cancer, when compared to non-small cell lung 
carcinoma (NSCLC), small cell lung carcinoma (SCLC) lines were 
more prone to spontaneous apoptosis [52]. Consequently, the absence 
 
Figure 1. Altered bioenergetics and genomic instability in lung cancer.  This comparison shows lung cancer alterations in bioenergetic signaling pathways, 
including a shift towards the reduced production of ATP using glycolysis instead of oxidative phosphorylation and the consequential impact on cancer initiation 
and progression. Additionally, mitochondrial dysfunction that occurs as a by-product of altered bioenergetics is displayed showing how genomic instability 
promotes tumorigenesis.  
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of spontaneous apoptosis and ineffective treatment-induced apoptosis 
in non-small cell lung carcinoma suggests that deficiencies in the 
apoptotic process may be responsible for their resistance to anti-
cancer therapy. 
Similar to other types of cancer, gene mutations (ie., p53, c-myc, 
Akt) and altered expression of apoptosis regulators are also detected 
in lung cancer. It has been suggested that different sensitivity to 
therapeutics that induce apoptosis may be related to the expression of 
apoptosis regulators in lung cancer [53]. Caspases, a family of cysteine 
proteases, are the central regulators of apoptosis. They mediate both 
forms of apoptosis--the intrinsic (which is activated by stress and 
controlled by the mitochondria) and extrinsic (which is activated by 
the death receptor pathway) apoptotic signaling cascades. Inactive 
pro-caspases are activated by cleavage cascades that signal to trigger 
downstream effectors, which cleave cellular substrates to induce 
apoptosis [54]. For example, studies show that small cell lung 
carcinoma cells, which are more prone to spontaneous apoptosis, are 
deficient in mRNA expression of extrinsic pro-caspases- , -4, -8, and 
- 0 [52] but no differences were observed between NSCLC and 
SCLC after examining the expression of intrinsic pro-caspases-2, -3, -
6, -7, -9 [55]. These data suggest that regulation or execution of 
caspases may contribute to apoptosis propensity.  
Inhibitors of apoptosis proteins (IAPs) prohibit cell death by 
binding and inactivating executioner caspases. IAPs work downstream 
of both mitochondria-mediated and death receptor-mediated 
apoptotic pathways. A study examining a panel of NCI human lung 
tumor cell lines detected overexpression of XIAP and CIAP  at the 
mRNA and protein level [56]. Additionally, the IAP-family protein 
Survivin, was highly overexpressed in lung tumor cell lines [57] and 
lung tumors [58]. Survivin has been shown to inhibit not only 
apoptosis induced by death receptor activation via FADD (Fas-
associated protein with death domain) but this IAP can inhibit 
programmed cell death due to Bax overexpression, which engages the 
apoptotic pathway at the level of mitochondria by inducing 
cytochrome c release [59]. It has been suggested that higher levels of 
Survivin protein are associated with more aggressive disease [60]. 
Furthermore, Survivin antisense molecules have been utilized clinically 
to sensitize lung cancer cells to chemotherapy [6 ]. 
The Bcl-2 family of proteins, which regulates apoptosis at the 
mitochondrial level [62], has a cell death dichotomy - Bcl-2, Bcl-xL, 
Bcl-w and Mcl-  family members inhibit apoptosis whereas Bax, Bak 
and Bok activate apoptosis. In multiple cancers, including certain lung 
cancers, anti-apoptotic proteins were amplified, suggesting that 
malignant cells could evade apoptosis via Bcl protein overactivation, 
signaling the cell to avoid cell death [63]. Cytochrome c release and 
apoptosis is initiated when BH3-only domain proteins, Puma and 
Bim, bind and inhibit pro-survival Bcl-2 family proteins. This protein 
inhibition allows pro-apoptotic Bax and Bak to permeabilize the outer 
mitochondrial membrane (MOMP) inducing apoptotic events 
through oligomerization [64]. Resistance to apoptosis has been 
observed in cells lacking Bim, Puma, and Bid, indicating that these 
proteins are needed to activate Bax and Bak to signal apoptosis [65]. 
In non-small cell lung cancer, anti-apoptotic Bcl-2 protein expression 
was higher in squamous cell carcinomas when compared to 
adenocarcinomas [66]. Furthermore, Bcl-2 protein expression 
correlates with nodal status in NSCLC and Bcl-2 immunostaining is 
considered a marker of loco-regional invasivity [67]. It has been 
shown that Bcl-2 protein expression is higher in SCLC than NSCLC 
[66]; however, another study demonstrated the development of SCLC 
was independent of Bcl-2 expression [68]. Bcl-2 family members 
control PTPC function [49]. Bcl-2 acts to keep the PTPC inactive 
through its interaction with VDAC. When PTPC is activated, Bax 
associates with VDAC and allows matrix solute influx, including 
calcium and other ions, which promote mitochondrial permeability 
transition through depolarization of the mitochondrial membrane. 
This leads to MOMP and the subsequent release of intermembrane 
space proteins, such as cytochrome c .   
Paradoxically in NSCLC, using immunohistochemical analysis to 
evaluate Bax expression, there is frequent high expression of pro-
apoptotic Bax during neoplastic proliferation. However, no 
correlation was identified between Bax expression and 
clinicopathologic parameters (ie., tumor grade, histological type) [69]. 
Despite this, in lung and other tumor types, there is a trend such that 
anti-apoptotic proteins are active in early tumor formation while pro-
apoptotic proteins are inhibited [70].  
Following cytochrome c release, the next step in the intrinsic 
pathway of apoptosis is apoptosome formation. The apoptosome is a 
large ternary protein structure that upon formation activates pro-
caspase-9, which subsequently activates other caspases triggering 
apoptosis [7 ]. Alterations in the expression of proteins that regulate 
apoptosome formation have also been proposed to play a role in 
carcinogenesis, including overexpression of HSPs (heat shock 
proteins). HSPs are a family of conserved proteins that protect the 
cell and are induced in response to a variety of cellular stressors. 
Defects in apoptosome formation have been found in lung cancer, 
including the overexpression of HSPs [72], which has been found to 
be correlated with poorer clinical outcomes and decreased 
responsiveness to chemotherapy in other cancer types [73].  
The tumor suppressor gene p53 plays a critical role in not just in 
cell cycle checkpoints, DNA repair and recombination [74] but also 
apoptosis [75]. Expression of p53 induces expression of death 
effector and mitochondrial apoptotic pathways. Defects in the p53 
pathway are common in lung cancer. Approximately 50% of all lung 
cancers exhibit dysfunctional p53 protein with p53 mutations 
detected in 50% of NSCLC [76] and 90% of SCLC [77]. In many 
human cancers, p53 is present as an inactive gene. This inactive form 
of p53 appears to allow tumor cells to avoid cell senescence and 
continue proliferating [78]. However, no relationship has been 
identified between the mutational status of p53 and the susceptibility 
of either SCLC or NSCLC to undergo apoptosis [55]. Additionally, 
p53 up-regulated modulator of apoptosis (PUMA) plays a major role 
in p53 dependent apoptosis [79] and in the absence of PUMA, cells 
are resistant to apoptosis [80] and carcinogenesis is promoted [8 ]. In 
human NSCLC cell lines that harbor wild-type p53, it has been 
shown that a small molecule that disrupts p53 binding, which 
activates p53 and promotes apoptosis via the induction of 
downstream target pro-apoptotic BH3-only genes, Noxa and PUMA 
[82].  
Currently, cancer therapeutics target various aspects of the 
apoptotic pathway. Anti-apoptotic modulating therapy is a promising 
strategy for cancer drug discovery and many groups are investigating 
the effects of Bcl-2, Bcl-xL or XIAP inhibition using antisense 
oligonucleotides and small mimetic molecules. For instance, in vitro 
studies are utilizing a BH3 domain small molecule mimetic that 
functions as a Bcl-2 inhibitor, which binds with high affinity to anti-
apoptotic proteins Bcl-2 and Bcl-xL leaving Bax or Bak oligomers free 
to permeabilize the outer mitochondrial membrane. This process 
releases cytochrome c from the mitochondria, activates caspase-3 and 
promotes cell death [83]. A Bcl-2 mimetic, ABT-737, potentiates 
anticancer treatments in small cell lung cancer xenograft models 
[84,85]. Previous studies have suggested that multiple points in the 
apoptotic pathway may need to be targeted to effectively induce 
programmed cell death, such as the IAP Survivin [58], Bcl-2 related 
protein Mcl-  (myeloid cell leukemia sequence ) inhibition or Bak 
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induction [86]. In SCLC and some pulmonary carcinoid tumors, a 
combination of chemotherapy agents, specifically those that down 
regulate Mcl- , and Navitoclax, a drug that inhibits anti-apoptotic Bcl 
proteins, has had some success decreasing tumor size; patients who 
received the combination treatment for longer than one year displayed 
a 22% - 35% decrease in tumor size [87]. Both SCLC and pulmonary 
carcinoid tumors are characterized by having high expression of Bcl-2 
expression and the chemotherapy resistance commonly seen in these 
types of cancer suggests dependence on anti-apoptotic proteins [87]. 
Another therapy utilized an EGFR  (epidermal growth factor 
receptor) antagonist, which prevented promotion of Akt survival 
signaling [88] and inhibited cancer cell proliferation.  Conversely, 
pro-apoptotic modulating anti-cancer drugs are also being studied. 
Direct activation of executioner caspases like caspase-3 [89] or 
stimulation of cell death receptors involving the extrinsic apoptotic 
pathway has induced apoptosis and limited cell growth in lung cancer 
cell lines [90]. Lastly, gene replacement therapy to restore mutated 
cancer suppressor gene function is another promising strategy for 
cancer treatment. Restoration of p53 or inactivation of Akt by PTEN 
(phosphatase and tensin homolog) gene delivery inhibited lung 
tumorigenesis [9 ] and suppression of Akt by programmed cell death 
4 (PDCD4) induced apoptosis in a mouse model of lung cancer [92].  
Figure 2 illustrates the intrinsic and extrinsic apoptotic pathways 
that are involved implicated in lung cancer progression. Impairments 
in apoptosis play a central role in cancer progression and as such, 
scientists are exploring the components that engage the cell death 
machinery to circumvent oncogenesis. An increasing number of 
studies are investigating the process of mitochondrial dynamics and 















Figure 2. Mitochondrial pathways: interactions between apoptotic signaling and mitochondrial dynamics. Visualized is the complex array of proteins and 
signaling molecules that are involved in normal apoptotic signaling, both extrinsic and intrinsic, and the interaction of mitochondrial dynamics players that 
modify mitochondrial morphology and consequentially impact apoptotic regulation. Green colored text indicates pro-apoptotic signaling and red colored text 
indicates anti-apoptotic signaling. 
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Mitochondrial dynamics and tumorigenesis of the lung 
 
The process of mitochondrial dynamics, the continuous cycle of 
fission and fusion, maintains mitochondrial morphology and function 
[93]. Solid evidence has shown that mitochondrial dynamics 
manipulates mitochondrial function including cell death and 
metabolism [94]. Figure 2 illustrates the complex interaction of 
mitochondrial dynamics proteins in apoptotic signaling and control of 
mitochondrial morphology. Defects in mitochondrial dynamics have 
been recently brought to the forefront of neurodegenerative 
therapeutic modeling, for diseases such as Parkinson and Alzheimer 
disease [95]. The number of studies investigating the role of 
mitochondrial function in cancer is on the rise, but understanding the 
recent contributions made in the field of mitochondrial dynamics may 
impact our comprehension of tumorigenesis and cancer progression. If 
we manipulate mitochondrial dynamics to sensitize tumor cells to 
apoptosis, then site-directed therapeutics could potentially be applied 
in cancer. 
The mitochondrion plays a complex role during apoptosis. The 
mitochondrial stage of apoptosis control is upstream of caspase 
activation and is mediated by the Bcl-2 family of proteins. Upon the 
initiation of apoptosis, BH3-only proteins are induced and bind anti-
apoptotic Bcl-2 proteins, which allow pro-apoptotic Bax and Bak to 
permeabilize the outer mitochondrial membrane releasing cytochrome 
c and activating the caspase signaling cascade [96]. Upstream of 
caspase activation and prior to or during cytochrome c release, a 
mitochondrion undergoes a division whereby the mitochondrial 
network segregates into smaller units—this process is called 
mitochondrial fission [97]. Mitochondria are dynamic organelles that 
constantly divide and fuse to form a mobile, interconnected network 
of mitochondrial units. The opposing process of fission is the joining 
of two mitochondria, mitochondrial fusion, which promotes 
elongated and reticular mitochondrial phenotypes [98]. 
Mitochondrial dynamics is the balance between mitochondrial fission 
and fusion events that regulate the shape, structure and function of 
the mitochondrion.  
Mitochondrial fragmentation or fission is associated with 
apoptosis; however, excessive mitochondrial fission can occur in the 
absence of programmed cell death [96,99]. For instance, reversible 
uncoupling of the inner mitochondrial membrane by depolarizing 
agents fragments the mitochondria during treatment. With drug 
removal the mitochondria repolarize and fuse together to form a 
healthy network [ 00]. Excessive mitochondrial fission is essential for 
intrinsic apoptosis—it is necessary for cytochrome c release and 
downstream caspase activation [ 0 , 02]. Additionally, 
mitochondrial fission proteins Drp  (Dynamin-related protein ; a 
large GTPase), Fis  (an assembly protein for Drp  mitochondrial 
recruitment in yeast), MARCH5 (a mitochondrial E3 ubiquitin 
ligase) and EndoB  (Endophilin B ; BAR domain-containing 
protein) have been associated with apoptosis [ 03- 05].  
During apoptotic initiation, Drp  is recruited from the cytoplasm 
to the outer mitochondrial membrane [ 0 , 06- 08], where it 
colocalizes with pro-apoptotic Bax and mitochondrial fusion protein 
Mfn2 (Mitofusin 2). Downregulation of Drp  limits mitochondrial 
fragmentation, cytochrome c release, caspase activation and apoptosis 
[ 0 , 07, 09- ]. Adenocarcinomic alveolar epithelial cells, a 
model of NSCLC, have displayed decreased Drp  protein expression, 
which promotes elongation of mitochondrial phenotypes and limits 
fission while inhibiting the downstream processes of apoptotic 
activation [ 2]. Inhibition of fission can also lead to other forms of 
mitochondrial dysfunction, including loss of mtDNA, increased ROS 
and ATP depletion [ 3]. Furthermore, dysfunctional mitochondrial 
fission in cancer cells directly induces chromosomal instability and 
centrosome overamplification, which can then initiate the DNA 
damage response through the modification of the cell cycle to 
promote survival [ 4]. These observations suggest the mitochondrial 
fission machinery could be a putative target to induce apoptosis 
through overexpression of Drp  in tumors.  
Drp  function is controlled by post-translational modifications, 
which have also been shown to influence mitochondrial morphology 
and subsequent apoptosis [ 5]. Post-translational modifications of 
Drp  influence cell sensitivity to apoptosis by its interaction with 
Bax/Bak, which is stabilized after mitochondrial fragmentation but 
prior to cytochrome c release [ 08]. In other cancer models, 
ubiquitylation and degradation of Drp  is important for maintaining 
mitochondrial biogenesis and metabolic function during interphase of 
the cell cycle [ 6]. The implications of Drp  phosphorylation are 
perplexing – there seems to be both activating (S585; S6 6) 
[ 7, 8] and inhibiting (S637) [ 9] Drp  phosphorylation sites 
that influence fission. Phosphorylation of Drp  S585 by cyclin—
dependent kinase  (Cdk )/cyclin B during mitosis allows the equal 
distribution of mitochondria into daughter cells during cytokinesis 
[ 8]. Overexpression of cyclin B , the regulatory subunit for Cdk , 
is overexpressed in non-small cell lung cancer and its upregulation is 
closely associated with poor prognosis [ 20]. Currently, inhibition of 
cyclin-dependent kinases, such as Cdk , is being considered as a 
therapeutic target to increase the sensitivity of cancer cells to extrinsic 
cell death [ 2 ] and prohibit metastatic processes [ 22].  
If modulation of mitochondrial fission players is a viable 
therapeutic, then the role of Fis1, MARCH5 and EndoB1 in cancer 
progression should also be considered. The downregulation of Fis  
inhibits mitochondrial fragmentation and reduces apoptosis 
[ 05, 23] while prohibiting Bax translocation and activation [ ]. 
So, Drp  and Fis  appear to act at different steps in the 
mitochondrial fission pathway. Ubiquitin-dependent degradation 
pathways are connected to cancer promotion because of their integral 
involvement in protein quality control, signal transduction, and the 
regulation of immune responses [ 24], so MARCH5 is another 
putative target for intervention in cancer. Overexpression of 
MARCH5 promotes ubiquitination of Drp  and the formation of 
elongated, reticular mitochondria in an Mfn2-dependent manner 
[ 24]; whereas, mutations in MARCH5 cause fragmentation of the 
mitochondria [ 25] which promotes apoptotic initiation. Lastly, 
Endophilin B  (EndoB ) [ 26- 28] is a cytosolic protein that 
transiently interacts with Bax on the mitochondria. EndoB  binds Bax 
to promote division of the mitochondrial membrane. EndoB  
knockout mice show increased rate of spontaneous tumor 
development [ 29] and downregulation of EndoB  blocks Bax 
translocation and cytochrome c release induced by apoptotic stimuli 
[ 30]. Manipulation of these fission players greatly impacts the onset 
of apoptosis.  
Mitochondrial fragmentation by the accumulation of fission 
proteins on the mitochondrial membrane mediates apoptosis. But 
during Bax foci formation during apoptotic initiation, the 
compensatory mitochondrial dynamics function, mitochondrial 
fusion, is blocked [ 04]. Three large GTPases in the dynamin family 
mediate mitochondrial fusion: mitofusins  and 2 (Mfn  and Mfn2) 
and optic atrophy protein  (Opa ) [ 5]. It has been shown that 
inhibition of mitochondrial fusion promotes apoptosis— (Mfn /2) 
silencing promotes mitochondrial fragmentation and increases 
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apoptotic cell death [ 3 ]. Evidence has demonstrated that 
mitofusins are regulated in both post-transcriptional and post-
translational fashion to govern their function [ 32]. A study 
examining NSCLC patient tissue has identified an alternatively 
spliced isoform of Mfn  that has upregulated expression at the 
mRNA level [ 33] that would limit apoptotic action in these cancer 
cells if protein expression of Mfn  matched mRNA expression. Mfn2 
has also exerted a regulatory role on the cell cycle that impacts cellular 
proliferation; it was originally named “hyperplasia suppressor gene, 
HSG” [ 32]. Mfn2 overexpression limited S and G2/M phases while 
promoting G0/G  growth through the binding and sequestration of 
Ras that ultimately causes cell cycle arrest and inhibits cell 
proliferation [ 34].  
The anti-proliferative function of mitochondrial fusion proteins is 
supported by the observation that Opa  is physically associated with 
prohibitins (PHB /2; inner mitochondrial membrane proteins that 
also regulate the cell cycle and apoptotic processes) to regulate cellular 
proliferation [ 35]. However, the loss of Opa , induces spontaneous 
apoptosis [ 36]. It has been shown that Bcl-2 overexpression can 
prevent cell death caused by Opa  silencing, which suggests that 
mitochondrial fusion precedes mitochondrial membrane 
permeabilization in cell death. Interestingly, silencing Opa  
expression in vitro reduced cisplatin resistance, a platinum-containing 
anti-cancer drug that is given intravenously to treat solid malignancies, 
and increased the release of cytochrome c from the mitochondria to 
signal the caspase-dependent apoptotic cascade [ 37]. Alternatively, 
overexpression of these mitochondrial fusion proteins elongates the 
mitochondrial network and inhibits Bax activation, cytochrome c 
release and apoptosis [ 38]. Overexpression of Opa  prevents 
intrinsic mediated apoptosis, but it does not block apoptosis induced 
through the extrinsic apoptosis pathway [ 39]. In lung 
adenocarcinoma cells, Opa  is highly expressed and indicates poor 
prognosis [ 37].  
Pro-apoptotic Bcl-2 family members, Bax and Bak also regulate 
mitochondrial morphology [96]. In Bax/Bak double knock out cells, 
mitochondrial fusion is reduced and downregulation of Drp  in these 
cells does not promote elongation [96]. This suggests that Bax and 
Bak activate mitochondrial fusion without disrupting the normal 
fission process. It is unknown how Bax and Bak promote 
mitochondrial fusion in healthy cells but remain an integral part of 
mitochondrial fission. Cancer cells may confer resistance to apoptotic 
stimuli as a result of a functional loss of proapoptotic proteins 
and/or increased expression of antiapoptotic proteins.  
Some theories suggest that mitochondrial dynamics participate in 
mitochondrial membrane permeabilization (MMP) - the point of no 
return during apoptosis [ 40], during which lipids and components 
of the fusion/fission machinery act concertedly to remodel 
mitochondrial membranes [ 04, 4 - 43]. Models suggest that upon 
apoptosis induction EndoB , Bax, and Drp  translocate to Mfn2-
mitochondrial foci to mediate vesicle scission, removing lipids from 
the outer mitochondrial membrane. As a result of EndoB  lipid 
deformation activity, Bax and Bak induce permeabilization of 
membranes through pore formation (MOMP; mitochondrial outer 
membrane permeabilization) which allows for cytochrome c release 
[ 42]. 
Another theory proposes that mitochondrial dynamics proteins 
regulate cristae remodeling, which favors MMP. Cristae 
rearrangements are thought to increase apoptotic sensitivity by 
promoting the release of cytochrome c [ 44]. Moreover, two pools of 
cytochrome c have been identified whereby, the major pool is retained 
in the cristae and binds cardiolipin (an important component of the 
inner mitochondrial membrane) and the minor, soluble pool of 
cytochrome c is present in the intermembrane space [ 44- 46]. 
Release of membrane-bound cytochrome c requires efficient 
mitochondrial fission [ 0, 36]. 
Some controversy still exists regarding the role of mitochondrial 
dynamics in apoptosis. It has been suggested that various stimuli 
impact mitochondrial fission and MMP [ 47], which can profoundly 
impact the degree of cell death. More studies are required to 
determine how mitochondrial fragmentation contributes to apoptosis 
and promotes tumor progression. It is necessary to identify the 
contributions of mitochondrial dynamics proteins in healthy versus 
apoptotic cells to clarify the definitive role of mitochondrial dynamics 




Mitochondrial function widely impacts dozens of diseases that 
affect millions of people worldwide. Defects in mitochondrial 
function are now being acknowledged in the etiology of cancer. 
Nearly 70 years after the Warburg hypothesis, mitochondrial 
function is at the crux of cancer biology and therapeutics. Alterations 
in mitochondrial function have been identified in neoplastic 
transformation and/or metastasis. A prominent example of 
mitochondrial dysfunction in cancer is the prominence of mtDNA 
mutations. As discussed previously, mitochondrial fusion is necessary 
to maintain the mitochondrial genome. Additionally, since 
mitochondrial division is also essential for the elimination of damaged 
mitochondria, any deficits in mitochondrial fission may contribute to 
the accumulation of dysfunctional mitochondria. It is possible that an 
imbalance in mitochondrial dynamics could contribute to the loss of 
mtDNA that is observed in cancer. This information could ultimately 
be used to develop novel approaches that identify the modification of 
the activity of affected genes to either prevent or treat cancer. By 
understanding the alterations in these processes that influence cancer 
metabolism, more effective treatments can be developed to target 
specific cancer cells based on their mitochondrial metabolic profile to 
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